Brokerages like Citi and Choice Institutional Equities are optimistic about the pharmaceutical and flexible workspace sectors. Citi maintains a ‘Buy’ on Lupin and Sun Pharma, citing strong US growth and product pipelines. Choice Institutional Equities initiates ‘Buy’ coverage on Smartworks, highlighting India’s booming flexible workspace market and the company’s strong position for significant expansion.
Source link
Buy, Sell or Hold: Citi maintains buy on largecap pharma stocks like Lupin & Sun Pharma